-
1
-
-
73249143536
-
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
-
Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28
-
(2010)
Lancet Oncol
, vol.11
, pp. 21-28
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
-
2
-
-
79956014003
-
Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer
-
Grimminger PP, Danenberg P, Dellas K et al (2011) Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res 17:3469-3477
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3469-3477
-
-
Grimminger, P.P.1
Danenberg, P.2
Dellas, K.3
-
3
-
-
79960352442
-
Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression
-
Gurtner K, Deuse Y, Bütof R et al (2011) Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 99:323-330
-
(2011)
Radiother Oncol
, vol.99
, pp. 323-330
-
-
Gurtner, K.1
Deuse, Y.2
Bütof, R.3
-
4
-
-
79959587751
-
Combined treatment of non-small-cell lung cancer stage III with intensity-modulated radiotherapy and cetuximab: The NEAR trial
-
Jensen AD, Münter MW, Bischoff HG et al (2011) Combined treatment of non-small-cell lung cancer stage III with intensity-modulated radiotherapy and cetuximab: The NEAR trial. Cancer 117:2986-2994
-
(2011)
Cancer
, vol.117
, pp. 2986-2994
-
-
Jensen, A.D.1
Münter, M.W.2
Bischoff, H.G.3
-
5
-
-
77949886293
-
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
-
Khambata-Ford S, Harbison CT, Hart LL et al (2010) Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28:918-927
-
(2010)
J Clin Oncol
, vol.28
, pp. 918-927
-
-
Khambata-Ford, S.1
Harbison, C.T.2
Hart, L.L.3
-
6
-
-
79952075689
-
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06)
-
Ruhstaller T, Pless M, Dietrich D et al (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 29:626-631
-
(2011)
J Clin Oncol
, vol.29
, pp. 626-631
-
-
Ruhstaller, T.1
Pless, M.2
Dietrich, D.3
-
7
-
-
38149088836
-
Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity
-
Safran H, Suntharalingam M, Dipetrillo T et al (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391-395
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.70
, pp. 391-395
-
-
Safran, H.1
Suntharalingam, M.2
Dipetrillo, T.3
|